Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.88% | -54.99% | -79.04% | -19.24% | -60.91% |
| Total Depreciation and Amortization | -34.41% | -20.42% | -19.31% | -93.43% | 26.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.88% | 22.43% | -1.66% | -74.19% | -57.71% |
| Change in Net Operating Assets | -2,132.61% | 42.57% | -179.45% | -91.81% | 172.69% |
| Cash from Operations | -24.97% | -63.65% | -104.88% | -92.98% | -73.68% |
| Capital Expenditure | 56.66% | 59.62% | -- | -137.50% | 27.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 249.58% | 22.04% | 170.01% | 62.98% | -274.16% |
| Cash from Investing | 248.91% | 22.17% | 169.95% | 62.93% | -276.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.29% | 263.81% | -94.98% | -72.62% | 24,119.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.62% | 100.00% | 98.01% | 88.90% | -2,848.05% |
| Cash from Financing | -95.57% | 607.41% | -94.80% | -82.14% | 1,485.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.53% | -93.08% | 248.59% | -1,048.49% | 277.93% |